Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615985 | 0.89 | NOTUM (0.78) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL17993966 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL11711879 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL10738426 | 0.78 | NOTUM (1.00) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL11831417 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL4582384 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL311636 | 0.78 | MAPT (1.00) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL82595 | 0.78 | MAPT (0.69) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL11118984 | 0.78 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL8485436 | 0.78 | KCNJ1 (0.66) | NOTUMMAPTF2KCNJ1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250354659-A1 | SYSTEM AND METHOD FOR STORING LIQUIDS HAVING LOW LATENT HEAT OF VAPORIZATION | NUOVO PIGNONE TECNOLOGIE – S R L (IT) | 2025-11-20 | — | — | US | claimed |
| WO-2025238576-A1 | SYSTEM AND METHOD FOR STORING LIQUIDS HAVING LOW LATENT HEAT OF VAPORIZATION | Nuovo Pignone Tecnologie – S.r.l. (IT) | 2025-11-20 | — | — | WO | claimed |
| CN-117720789-B | Low-smoke halogen-free fireproof flame-retardant power cable and preparation method thereof | 天津市天鸿祥线缆有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117720789-A | Low-smoke halogen-free fireproof flame-retardant power cable and preparation method thereof | 天津市天鸿祥线缆有限公司 | 2024-03-19 | — | — | CN | claimed |
| US-20070102076-A1 | Gas-producing mixtures | DELPHI TECHNOLOGIES, INC. (US) | 2007-05-10 | — | — | US | claimed |
| CN-1183758-A | Gas-generating mixture | DYNAMIT NOBEL AG (DE) | 1998-06-03 | — | — | CN | claimed |
| EP-0809616-A1 | GAS-GENERATING MIXTURES | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 1997-12-03 | — | — | EP | claimed |
| WO-1996026169-A1 | GAS-GENERATING MIXTURES | DYNAMIT NOBEL GMBH (DE) | 1996-08-29 | — | — | WO | claimed |
| WO-2026102259-A1 | SYSTEM AND METHOD FOR TARGETED GAS DESORPTION FROM SORBENTS VIA AN EDUCTOR PUMP MECHANISM | MOSAIC MATERIALS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260131275-A1 | SYSTEM AND METHOD FOR TARGETED GAS DESORPTION FROM SORBENTS VIA AN EDUCTOR PUMP MECHANISM | MOSAIC MAT INC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2025238576-A1 | SYSTEM AND METHOD FOR STORING LIQUIDS HAVING LOW LATENT HEAT OF VAPORIZATION | Nuovo Pignone Tecnologie – S.r.l. (IT) | 2025-11-20 | — | — | WO | disclosed |
| US-20250354659-A1 | SYSTEM AND METHOD FOR STORING LIQUIDS HAVING LOW LATENT HEAT OF VAPORIZATION | NUOVO PIGNONE TECNOLOGIE – S R L (IT) | 2025-11-20 | — | — | US | disclosed |
| US-20240327452-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARM INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-11958879-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0884311-A2 | Triazole Derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1998-12-16 | — | — | EP | disclosed |
| CN-1183758-A | Gas-generating mixture | DYNAMIT NOBEL AG (DE) | 1998-06-03 | — | — | CN | disclosed |
| EP-0809616-A1 | GAS-GENERATING MIXTURES | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996026169-A1 | GAS-GENERATING MIXTURES | DYNAMIT NOBEL GMBH (DE) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958879-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | NOTUM 1220/4885MAPT 1709/4885F2 3477/4885 |
| US-20260131275-A1 | SYSTEM AND METHOD FOR TARGETED GAS DESORPTION FROM SORBENTS VIA AN EDUCTOR PUMP MECHANISM | EXOSC9, EXOSC4, EXOSC5 | NOTUM 1839/4885MAPT 3402/4885F2 672/4885 |
| US-20240327452-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | GPBAR1, NR1H4, SLC10A1 | NOTUM 1220/4885MAPT 1709/4885F2 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.